Isolated local-regional recurrence after mastectomy: radiotherapeutic management
ForFirst isolated LRR after mastectomy, no prior PMRT, no distant mets
TL;DR5-yr freedom from chest wall re-recurrence 75% with whole-chest-wall fields vs 36% with small fields (p=0.0001) in 224 pts irradiated for isolated LRR.
Field size carries the strongest signal: 67% of small-field failures landed outside the portal but within the chest wall, supporting whole-CW coverage. Elective SCV RT cut SCV failure 16% to 6%, while elective axillary RT raised arm edema 11% vs 1%, so cover the SCV fossa and leave the uninvolved axilla alone.
In a first isolated chest wall or nodal recurrence after mastectomy without prior PMRT, this supports whole-chest-wall plus supraclavicular coverage over involved-field RT; it does not extend to re-irradiation after prior PMRT or to the elective uninvolved axilla.
Two thirds of small-field failures landed outside the portal but within the chest wall, supporting whole-CW coverage. Elective SCV RT cut SCV failure 16% to 6%, while elective axillary RT raised arm edema 11% vs 1%, arguing for SCV coverage and omission of the uninvolved axilla.
15 details
Single-institution retrospective review, Mallinckrodt Institute and affiliates, 1964-1986, N=224 irradiated with curative intent. Median follow-up 46 mo (range 24-241); actuarial life-table method.
First isolated local-regional recurrence after radical (34%), modified radical (61%) or total (5%) mastectomy. Excluded prior postmastectomy RT, pts failing salvage elsewhere, and clinical or radiographic distant mets. Chest wall alone in 134 (60%).
Entire chest wall via tangents, 1.5-6.0 MV to 4500-5000 cGy with bolus and a 6-12 MeV electron boost to gross disease; SCV AP field to 4500-5000 cGy at 3 cm. About 90% treated at 180-200 cGy/d; small 1-2 cm-margin fields used early in the series.
At recurrence, 49 pts received chemotherapy (most often CMF or CAF) and 69 hormonal therapy, usually tamoxifen. Combined-modality vs RT-alone analysis deferred to a later report.
5-yr LRC 57%; whole-CW fields gave 75% vs 36% 5-yr freedom from CW re-recurrence vs small fields (p=0.0001). For <3 cm lesions, 100% controlled at ≥6000 cGy vs 76% lower; larger lesions about 50% even at 7000 cGy.
| Site | 5-yr OS | 5-yr RFS | 5-yr LRC |
|---|---|---|---|
| Chest wall alone | 50% | 35% | 63% |
| Nodal alone | 36% | 15% | 45% |
| Chest wall + nodal | 19% | 5% | 27% |
| p | 0.0002 | 0.0001 | 0.0084 |
| Field | 5-yr | 10-yr |
|---|---|---|
| Large (entire CW) | 75% | 63% |
| Small (1-2 cm margin) | 36% | 18% |
| p | 0.0001 | 0.0001 |
| Uninvolved site | Elective RT | No RT | p |
|---|---|---|---|
| Supraclavicular fossa | 6% | 16% | 0.0489 |
| Chest wall (any dose) | 17% | 27% | .32 |
| Chest wall (≥5000 cGy) | 12% | 27% | .20 |
Grade 2 sequelae 9%, grade 3 1%, none fatal. Arm edema 11% vs 1% with vs without elective axillary RT; pneumonitis higher with a parasternal field (8% vs 2% tangents alone).
Toonkel and co-workers, cited here, found a survival advantage with comprehensive nodal RT, while Deutsch reported the opposite, with that elective-nodal group carrying more extensive disease. Chen saw 27% failure in an uninvolved site after involved-field RT, consistent with this series' case for elective CW and SCV coverage.
Small-field group was only 14 pts and clustered in the early era, so the field-size effect also captures changes in staging workup and systemic therapy. The elective CW p-value is printed as both .32 and .33, and dose was set by physician preference.
The pattern of failure argues the whole chest wall carries subclinical disease, which favors comprehensive fields over excision alone or small portals. Large, diffuse or combined CW-plus-nodal recurrences stay poorly controlled at any dose, and the authors point to hyperthermia, altered fractionation or systemic combinations in prospective trials.
Single-institution retrospective spanning 22 years; field size, dose and elective coverage chosen by era and physician preference, so selection and era effects confound every comparison.
- Elective nodal RT benefit with contemporary systemic therapy
- Better local control for large or diffuse chest wall recurrences
📚 Sources · 📄 1 paper
The longer read
The durable contribution of this series is its pattern-of-failure argument, not its survival figures. When a solitary chest wall recurrence was treated with a small portal, two thirds of subsequent failures arose outside the field yet within the chest wall. That is a biologic observation about where subclinical disease sits, and it is less sensitive to selection bias than any of the outcome comparisons, because it describes the anatomy of failure within the treated group rather than comparing groups chosen differently. It underpins the whole-chest-wall field that remains the default for an isolated recurrence in an unirradiated chest wall.
The headline field-size comparison deserves less confidence than its p-value suggests. Small fields were used in only 14 pts and belonged to the early part of a 22-year window, before the institution switched policy after seeing frequent relapses. The workup for occult metastases also became more extensive over time, and systemic therapy at recurrence changed. A reader should treat the 75% versus 36% gap as directionally right and its magnitude as unreliable: era, staging intensity and case selection all move with field size here.
The elective coverage findings separate into a credible signal and a weaker one. Supraclavicular failure fell from 16% to 6% with elective SCV RT, a site-specific endpoint where the mechanism is direct. The accompanying survival difference, 53% versus 35%, is harder to accept; elective coverage was more common later in the series and in pts the treating physician judged suitable for larger volumes, and a regional nodal field preventing distant death is a large claim from retrospective data. The elective chest wall result did not reach statistical significance, and the paper reports its p-value inconsistently, but the observation that untreated chest walls kept failing as late as 8 and 11 years while treated ones did not after 3 years is the more informative detail for a reader weighing long-term risk in a pt with a long disease-free interval.
The toxicity data are the most transferable to modern practice. Arm edema concentrated in pts given elective axillary RT, and axillary re-recurrence in an uninvolved axilla was uncommon regardless of treatment, which makes omission of the dissected, uninvolved axilla a defensible position that later practice has largely adopted. The pneumonitis gradient with an added parasternal field reflects 2D technique and would need re-evaluation with CT planning.
The dose findings should be read as a ceiling, not a recipe. Small excised or sub-3 cm lesions were controlled reliably, while large, multiple or diffuse disease sat near 50% control without a dose response. That points away from escalation as the answer for bulky recurrence and toward systemic integration, which this paper explicitly deferred. Later work on chemotherapy after isolated locoregional recurrence, such as CALOR, addressed that question directly, and the modern reader will layer endocrine and HER2-directed therapy onto the volumes this paper defined. What would make this series wrong is a demonstration that, with modern imaging, recurrences selected for small fields were genuinely confined; nothing in these data rules that out, but nothing supports it either.